Walleye Capital LLC Makes New $668,000 Investment in AbCellera Biologics Inc. (NASDAQ:ABCL)

Walleye Capital LLC purchased a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 256,881 shares of the company's stock, valued at approximately $668,000. Walleye Capital LLC owned 0.09% of AbCellera Biologics as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Arcadia Investment Management Corp MI acquired a new stake in AbCellera Biologics in the 3rd quarter valued at approximately $26,000. Evergreen Capital Management LLC acquired a new stake in shares of AbCellera Biologics in the second quarter valued at $32,000. NBC Securities Inc. raised its holdings in shares of AbCellera Biologics by 56.0% in the 3rd quarter. NBC Securities Inc. now owns 11,420 shares of the company's stock valued at $29,000 after buying an additional 4,100 shares during the period. Ballentine Partners LLC purchased a new stake in shares of AbCellera Biologics in the 3rd quarter valued at $54,000. Finally, B. Riley Wealth Advisors Inc. lifted its stake in AbCellera Biologics by 104.8% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company's stock worth $64,000 after acquiring an additional 11,000 shares in the last quarter. 61.42% of the stock is currently owned by institutional investors and hedge funds.

AbCellera Biologics Trading Up 5.3 %

NASDAQ:ABCL traded up $0.15 during midday trading on Friday, reaching $3.00. The company had a trading volume of 2,371,018 shares, compared to its average volume of 2,577,610. AbCellera Biologics Inc. has a 12-month low of $2.34 and a 12-month high of $6.05. The firm has a market capitalization of $886.11 million, a price-to-earnings ratio of -4.92 and a beta of 0.41. The stock's fifty day simple moving average is $2.75 and its 200-day simple moving average is $2.90.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The company had revenue of $6.51 million during the quarter, compared to analysts' expectations of $8.95 million. During the same quarter in the previous year, the business posted ($0.10) EPS. As a group, sell-side analysts expect that AbCellera Biologics Inc. will post -0.59 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on ABCL. Benchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a research report on Tuesday, November 5th. Stifel Nicolaus restated a "buy" rating and issued a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.